Roche vice-chair: Let’s repair the damage that short-term profit drive has done to the planet – Endpoints News

Count Pfizer in as a top player in the blockbuster game of JAK1 inhibitors.

Over the weekend the pharma giant posted some stellar Phase III efficacy data for their heavyweight contender abrocitinib in atopic dermatitis (eczema) that lines up ahead of a booming Dupixent (dupilumab), a blockbuster in the portfolios of Regeneron and Sanofi. And they put some real distance ahead of Eli Lillys trailing Olumiant, which made a delayed initial arrival on the market for rheumatoid arthritis after the FDA hobbled it with some additional hurdles on safety concerns.

JADE-MONO-1 scores well for Pfizer, teeing up what will be an intensely followed breakdown of the JADE MONO-2 data, which the pharma giant recently top-lined as similar to the first Phase III when tested against a placebo a control group that has been easily outclassed by all the drugs in this market niche.

As of now, Pfizer looks to be equipped to run into the review stage advantaged by a breakthrough therapy designation that is intended to speed up the regulatory process.

Unlock this story instantly and join 62,100+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

Read the rest here:
Roche vice-chair: Let's repair the damage that short-term profit drive has done to the planet - Endpoints News

Related Post